Medication info
Agril Tablet 2 mg (Glymeperide)

Agril Tablet 2 mg (Glymeperide)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Ari Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201906464 · Approved 2019.09.16 · Insurance code 058200120

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. Monotherapy Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses greater than 4 mg, although some patients achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. Secondary dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. Switching from another oral antihyperglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this medicine, it is recommended to follow the method described under Initial dose. That is, treatment may be initiated at 1 mg once daily, with dose adjustments at intervals of 1 ~ 2 weeks. The efficacy and duration of action of the previous medication should be considered. Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medicine, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur despite initially successful management during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. Combination therapy Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is administered at 8 mg once daily with the first meal, and insulin is initiated at a low dose and increased approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia with concomitant use of this medicine and metformin, and the risk may be increased. Appropriate caution should be exercised.

Ingredients

Manufacturer
Ari Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes by complementing dietary and exercise regimens. It can be administered alone and may be used in conjunction with insulin if insufficient blood sugar control is achieved with oral hypoglycemic agents alone. Additionally, when there is inadequate efficacy from either sulfonylureas or metformin monotherapy, it can be co-administered with metformin to enhance blood glucose control. This medication helps improve patients' blood sugar management.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. Monotherapy Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit with doses greater than 4 mg, although some patients achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. Secondary dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. Switching from another oral antihyperglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this medicine, it is recommended to follow the method described under Initial dose. That is, treatment may be initiated at 1 mg once daily, with dose adjustments at intervals of 1 ~ 2 weeks. The efficacy and duration of action of the previous medication should be considered. Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medicine, and regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur despite initially successful management during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. Combination therapy Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure when fasting blood glucose (FBG) exceeds 150 mg/dL. This medicine is administered at 8 mg once daily with the first meal, and insulin is initiated at a low dose and increased approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glyburide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to determine the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia with concomitant use of this medicine and metformin, and the risk may be increased. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or those in a coma. It is also prudent to avoid administering this medication to patients with an allergy to this drug or its components, severe liver or kidney dysfunction, or in pregnant or breastfeeding women. In patients with severe infections, major surgeries, or severe trauma, conversion to insulin therapy is recommended. Care is necessary as gastrointestinal issues can affect drug absorption leading to a risk of hypoglycemia. Patients with lactose intolerance or certain genetic metabolic disorders should not take this medication. During the first week of administration, the risk of hypoglycemia is high, so blood sugar status must be closely monitored, particularly in older adults, those with poor nutritional status, irregular meal patterns, those with impaired kidney or liver function, and those taking other medications. If hypoglycemic symptoms occur, sugar should be consumed immediately, and it is advisable to always carry sugar for this purpose. In case of severe hypoglycemia, immediate medical attention may be required, so one should go to the hospital promptly if symptoms occur. This medication must be used in conjunction with dietary and exercise therapy for blood sugar control and consistent intake is essential. There may be interactions with other medications, so it is crucial to inform healthcare providers about any other medications being taken. It is safest for pregnant or breastfeeding women not to use this medication and to consider switching to insulin therapy if necessary. Safety and efficacy have not been established in children under 18 years of age, so it should not be used in this population. In older adults, attention should be paid to dosage adjustment due to the common decline in renal function. In cases of overdose, severe hypoglycemia may occur, necessitating immediate first aid and professional treatment at a hospital. This medication should be stored out of reach of children and kept in its original container.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbances, anxiety, aggression, decreased concentration, decreased agility or drive, depression, confusion, speech abnormalities, aphasia, visual disturbances, tremors, incomplete paralysis, sensory abnormalities, dizziness, weakness, loss of self-control, temporary mental confusion, brain convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein issues, blurred vision, sensation of fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, bile secretion disorders, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, neutropenia, agranulocytosis, pancytopenia, allergy, itching, urticaria, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disorders, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, joint pain, dyspepsia, facial swelling, erectile dysfunction, flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a sealed container to prevent exposure to air or moisture, and it is suggested to store at room temperature between 1 to 30 degrees Celsius. Therefore, it is important to avoid direct sunlight and not to place the medication in excessively hot or cold locations to maintain its efficacy.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.